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Abstract
Proliferative retinopathy is a leading cause of blindness, including retinopathy of prematurity (ROP) in children and diabetic
retinopathy in adults. Retinopathy is characterized by an initial phase of vessel loss, leading to tissue ischemia and hypoxia,
followed by sight threatening pathologic neovascularization in the second phase. Previously we found that Sirtuin1 (Sirt1), a
metabolically dependent protein deacetylase, regulates vascular regeneration in a mouse model of oxygen-induced
proliferative retinopathy (OIR), as neuronal depletion of Sirt1 in retina worsens retinopathy. In this study we assessed
whether over-expression of Sirtuin1 in retinal neurons and vessels achieved by crossing Sirt1 over-expressing flox mice with
Nestin-Cre mice or Tie2-Cre mice, respectively, may protect against retinopathy. We found that over-expression of Sirt1 in
Nestin expressing retinal neurons does not impact vaso-obliteration or pathologic neovascularization in OIR, nor does it
influence neuronal degeneration in OIR. Similarly, increased expression of Sirt1 in Tie2 expressing vascular endothelial cells
and monocytes/macrophages does not protect retinal vessels in OIR. In addition to the genetic approaches, dietary
supplement with Sirt1 activators, resveratrol or SRT1720, were fed to wild type mice with OIR. Neither treatment showed
significant vaso-protective effects in retinopathy. Together these results indicate that although endogenous Sirt1 is
important as a stress-induced protector in retinopathy, over-expression of Sirt1 or treatment with small molecule activators
at the examined doses do not provide additional protection against retinopathy in mice. Further studies are needed to
examine in depth whether increasing levels of Sirt1 may serve as a potential therapeutic approach to treat or prevent
retinopathy.
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Introduction
Pathologic blood vessel proliferation is a leading cause of
blindness in proliferative retinopathy. This includes retinopathy of
prematurity (ROP), a complication of premature birth in children,
and diabetic retinopathy (DR), one of the most common
complications of diabetes in working age adults [1,2]. Finding
treatment options for retinopathy, which is critical for preventing
blindness in children and adults, depends on a better understand
of the disease pathogenesis. Retinopathy develops in two phases.
The first phase is vessel loss or regression of existing vessels after
premature birth in ROP, or due to abnormal metabolism in
diabetes in DR. Retinal vessel loss induces tissue ischemia and
hypoxia, leading to upregulation of angiogenic growth factors,
which then stimulate sight-threatening pathologic neovasculariza-
tion[2–8]. Recent research has paid increasing attention to the
interaction between retinal neurons and vessels in the pathogenesis
of retinopathy[9–11]. Understanding how retinal neurons respond
to ischemic insults and metabolic stress in retinopathy to regulate
vessel growth is important for the identification of new potential
therapies.
Previously we found that the presence of neuronal Sirtuin1, a
metabolically dependent protein deacetylase, is essential in
mediating neurovascular crosstalk and regulating vascular regen-
eration in a mouse model of oxygen-induced retinopathy (OIR),
which mimics ROP and some aspects of proliferative DR in
humans[12,13]. Sirt1 belongs to a family of class III histone
deacetylases, originally discovered to be important for calorie
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NAD+ as a co-activator[15]. Sirt1 is usually localized in the
nucleus, although it may also translocate to the cytoplasm, and
catalyzes deacetylation of various protein targets in addition to
histones[16]. Many of these Sirt1 substrates are transcription
factors such as PGC1a, FOXO, and HIF, whose activities are
altered by Sirt1 mediated deacetylation, leading to changed
expression of target genes[16–18]. Sirt1 has been associated with a
variety of biologic processes including oxidative stress, gene
silencing, and DNA repair, in addition to senescence, neurogen-
esis, circadian rhythms, neuroendocrine signals and dendritic
branching, all of which impact the nervous system during normal
physiologic functioning as well as with aging, and during
pathologic processes[19]. Within the brain Sirt1 is indispensable
for normal cognitive function[20] and its activation protects
against neurodegenerative diseases including Parkinson’s, Alzhei-
mer’s and Huntington’s disease in animal models[21–23]. In
addition to its role in neurons, Sirt1 also plays a role in blood vessel
growth during development through regulation of Notch signaling
[24], and FOXO1[25]. We found in a previous study that Sirt1 is
upregulated in retinal ganglion cells in the vaso-obliteration zone
in ischemic neuronal retina, and conditional depletion of Sirt1 in
retinal neurons significantly impaired vascular regrowth into the
avascular zone and precipitated pathologic neovascularization in
retinopathy[12]. These results suggest that Sirt1 is a critical stress-
induced metabolically dependent protector in retinopathy.
In this study we investigated whether upregulation of Sirt1 levels
or activity via genetic and pharmacologic approaches might
protect against retinopathy in a mouse model of OIR. Conditional
Sirt1 over-expression in retinal neurons or vessels was generated
by breeding Sirt1 over-expressing flox mice with Nestin-Cre or
Tie2-Cre mice, respectively. In addition, small molecule Sirt1
activators resveratrol and SRT1720[26,27] were orally supple-
mented in wild type mice before and during induction of
retinopathy to evaluate their potential effects. No significant
protection was observed with either over-expression of Sirt1 in
transgenic mice or with treatment of Sirt1 activators. These data
suggest that although induction of endogenous Sirt1 in ischemic
retina is critical under stress condition to protect against
retinopathy, over-expression of Sirt1 or treatment with small
molecule activators at the examined doses does not offer additional
protective effects in retinopathy in mice.
Methods
Animals
These studies were approved by the Children’s Hospital Boston
Animal Care and Use Committee. Sirt1 over-expression mice
were previously described[20]. Nestin-Cre mice (stock# 003771),
Tie2-Cre mice (stock# 004128), and C57Bl/6J mice (stock#
000664) were obtained from Jackson Laboratory.
Oxygen-induced retinopathy
Neonatal mice with their nursing mother were exposed to 75%
oxygen from P7 to P12 to induce retinopathy (OIR)[13]. After
returning to room air for 5 days, mice were sacrificed at P17, to
observe maximal retinal neovascular response.
Resveratrol and Sirt1 activator treatment
A micronized formulation of resveratrol, SRT501 (400 mg/kg
body weight in 10 mL of 2% HPMC, 0.2% DOSS, 1% sucrose in
water) or vehicle control was given daily from postnatal day (P) 5
to P17 by oral gavage to C57BL/6J mouse pups with induced
OIR. Similarly, SRT1720 (100 mg/kg body weight) or vehicle
control was given daily from P5 to P17 by oral gavage to C57BL/
6J mouse pups with OIR. Littermate pups were used in all
experiments for vehicle controls. SRT501 and SRT1720 were
provided by Sirtris Pharmaceuticals, Inc. (Cambridge, MA).
Retina dissection, staining and imaging
Mice were collected at P17 in OIR. They were anesthetized
with Avertin (Sigma-Aldrich) and sacrificed via cervical disloca-
tion. Eyes were enucleated, fixed in 4% paraformaldehyde in PBS
for 1 h, and dissected to isolate the retina. The retinas were
subsequently stained overnight with fluoresceinated Griffonia
Simplicifolia Isolectin B4 (Alexa Fluor 594 conjugated; I21413;
Invitrogen; 1:100 dilution) in PBS with 1 mM CaCl2 to visualize
vessels. After 2 hr washes in PBS, retinas were whole-mounted
with the photoreceptor side down onto Superfrost/Plus micro-
scope slides (12-550-15; Fisher Scientific) using SlowFade Antifade
reagent (S2828; Invitrogen). Whole-mounted retinas were imaged
at 56magnification on a Zeiss AxioObserver.Z1 microscope and
merged using AxioVision 4.6.3.0 software to produce images of
entire retinal vasculature.
Quantification of vessel loss and neovascularization in
OIR
Vascular loss and neovascularization in OIR were quantified as
previously described, using Adobe Photoshop or ImageJ[28–31].
By staining with Isolectin, the number of pixels in vascularized
areas was visualized, outlined in Photoshop, and compared to the
total number of pixels of the entire retina. From their abnormally
aggregated morphology that is distinctly different from the normal
branched vascular network, pathologic neovascular tuft structures
were visually identified. Pixel area of pathologic neovascular tufts
were quantified and compared to the total pixel area in whole
retina using the SWIFT_NV method, which consists of a set of
macros on NIH’s free ImageJ platform to distinguish and isolate
neovascular structures from the background fluorescence of
normal vessels[30]. Quantification of retinal vessels was performed
in a masked manner for the identity of samples. N is the number of
eyes quantified.
Quantification of retinal thickness in OIR
For retinal thickness measurements, eyes from P17 normoxia or
OIR exposed animals were enucleated, fixed in 4% paraformal-
dehyde in PBS at room temperature for 1 h, dehydrated with
increasing concentrations of ethanol and Xylene, followed by
paraffin embedding. 10 paraffin sections close to the optic nerve
were collected for each eye followed by H&E staining. For each
retinal section, two peripheral retinal and two central retinal
images were taken at 106 magnification on a Zeiss AxioObser-
ver.Z1 microscope. Retinal thickness in cross sections of eyes was
quantified in Adobe Photoshop. Using the Line Tool, the number
of pixels across retina was measured for each image and retinal
thickness was averaged for peripheral and central regions of each
group. Evaluation was performed in a masked manner for the
identity of samples. N is the number of eyes evaluated.
Retinal RNA isolation and gene expression analysis
Total RNA was extracted from retinas of at least 3 mice. Using
a mortar and pestle, retinas were lysed and subsequently filtered
through QiaShredder columns (Qiagen, Chatsworth, MD, USA).
RNA was extracted using the manufacturer’s instructions for the
RNeasy Kit (Qiagen). To generate cDNA, 1 mg total RNA was
first treated with DNase I (Ambion Inc.) to remove any
contaminating genomic DNA. Then, the RNA was reverse
Sirt1 Over-Expression Does Not Impact Retinopathy
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transcriptase (Invitrogen Corp., Carlsbad, CA, USA). All cDNA
samples were aliquoted and stored at 280uC.
The following primers were designed using Primer Bank and
NCBI Primer Blast Software: mouse Sirt1 (F: 59-GACGATGA-
CAGAACGTCACAC, R: 59-CGAGGATCGGTGCCAATCA),
MAO-A (F: 59-GTGAATGTCAATGAGCGTCTAGT, R: 59-
TCAACAGGGATCTCTTTTCCCA), PGC-1a (F: 59-
GGAGCCGTGACCACTGACA, R: 59-
TGGTTTGCTGCATGGTTCTG), and cyclophilin A (F: 59-
CAGACGCCACTGTCGCTTT, R: 59-
TGTCTTTGGAACTTTGTCTGCAA). ABI Prism 7700 Se-
quence Detection System (TaqMan) and SYBR Green Master mix
kit were used for the quantitative analysis of gene expression.
Standard curves for each gene were plotted with a quantified
cDNA template during real-time PCR reactions. The mRNA copy
number of each target gene was normalized to a million copies of
the housekeeping gene, cyclophilin A.
Western blot
Retinal lysate was loaded on a SDS-PAGE gel and transferred
onto a PVDF membrane. The membranes were blocked,
incubated overnight with primary antibody, and then incubated
for one hour at room temperature with secondary antibody
conjugated with horseradish peroxidase. Chemiluminescence
signals were generated with ECL plus substrate and captured
with KODAK film. The following primary antibodies were used
for Western Blot: anti-Sirt1 (Millipore, 07–131), anti-b-actin
(Sigma-Aldrich, A1978); secondary antibodies: donkey anti-rabbit
conjugated with horse-radish peroxidase (NA934V, Amersham
Pharmacia), sheet anti-mouse conjugated with horse-radish
peroxidase (NA931V, Amersham Pharmacia).
Immunohistochemistry
Eyes were fixed in 4% paraformaldehyde in PBS for 1 h,
incubated in 30% sucrose at 4uC, and embedded in OCT. 10-mm
thick cross sections were collected and blocked with PBS with
Figure 1. Sirt1 over-expression in retinal neurons of Nes-Sirt1
OE mice. a) Representative images of retinal cross-section with: (Left)
hematoxylin and eosin (H&E) staining showing three retinal neuronal layers: RGC, INL, ONL, and retinal pigment epithelium (RPE)/choroid; and (Right)
lectin (red) and DAPI (blue) staining showing retinal vasculature. RGC: Retinal ganglion cell, INL: inner nuclear layer, ONL: outer nuclear layer. b)
Neuronal or endothelial Sirt1 over-expressing mice (Nes-Sirt1
OE or Tie2-Sirt1
OE) were generated by crossing Sirt1 over-expressing flox mice with Nestin-
Cre or Tie2-Cre mice to result in over-expression of Sirt1 in Nestin or Tie-2 expressing cells. c) Increased nuclear Sirt1 levels were observed with
immunohistochemistry in retinal sections from Nes-Sirt1
OE mice compared to those from wild type (WT), flox control, Nestin-Cre controls. Sections
were stained with Sirt1 antibody (green) and counter stained with nuclear stain DAPI (blue). An area in Nes-Sirt1
OE retina is enlarged for visualization
of Sirt1 localization in nuclei. Scale bar: 50 mm. d) Sirt1 mRNA levels, measured by RT-qPCR, were significantly increased in the retinas of postnatal day
(P) 17 Nes-Sirt1
OE mice compared to littermate flox controls (n=3/group). e) Western blot analysis showed Sirt1 proteins levels were strongly
increased in adult retinas of Nes-Sirt1
OE mice compared to controls (n=4–5/group). f) Increased expression of MAO-A and PGC-1a in Nes-Sirt1
OE retinas
compared to flox control retinas (n=3/group). * p,0.05, ***p,0.001.
doi:10.1371/journal.pone.0085031.g001
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with primary anti-Sirt1 antibody (Millipore, 07-131) and second-
ary antibody staining (chicken anti-rabbit Alexa 488, A-21441,
Invitrogen), followed by mounting medium with DAPI.
Statistics
Results were presented as means 6 SEM and were analyzed
using a two-tailed student t test. P value #0.05 is considered
statistically significant.
Results
Generation of transgenic mice with conditional over-
expression of Sirt1 in retinal neurons
To evaluate the effects of increased Sirt1 levels in the retina, we
generated neuronal or vascular endothelial specific Sirt1 over-
expression mice (Nes-Sirt1
OE and Tie2-Sirt1
OE) by crossing Sirt1 flox
mice (Sirt1
flox/flox) with Nestin-Cre mice (Nestin-Cre
+/2) or Tie2-Cre
mice (Tie2-Cre
+/2) expressing Cre recombinase in Nestin or Tie2
positive cells, respectively (Fig. 1a,b). Over-expression of Sirt1
was confirmed with Sirt1 antibody staining in retinal cross sections
from WT control, flox control (Sirt1
flox/flox), Nestin-Cre (Nestin-Cre
+/
2), and Sirt1 OE mice (Nes-Sirt1
OE)( Fig. 1c). While all three
control groups showed basal levels of Sirt1 staining in the retinas,
substantially stronger nuclear staining of Sirt1 was observed in Nes-
Sirt1
OE retinas, particularly in the inner nuclear layer (INL). Levels
of retinal Sirt1 mRNA were quantified with RT-qPCR, showing
,4 fold upregulation of Sirt1 in Nes-Sirt1
OE retinas at P17
compared to littermate flox controls (Fig. 1d). A marked increase
in Sirt1 protein levels was also detected in Nes-Sirt1
OE retinas
compared to control retinas by Western blotting (Fig. 1e). In
order to confirm that increased Sirt1 correlates with the activation
of target genes, we analyzed expression of monoamine oxidase A
(MAO-A), which is regulated through Sirt1-dependent deacetyla-
tion of the brain-specific helix-loop-helix transcription factor
(NHLH2) to mediate anxiety and exploratory drive [32]. We also
measured the well-known Sirt1 substrate PGC-1a [17,33] which
was previously shown to be down regulated in Sirt1-deficient
retinas [12]. Our results show increased expression levels of MAO-
A, and PGC-1a in Nes-Sirt1
OE retinas, confirming the upregulation
of Sirt1-mediated pathways in retinas that overexpress this sirtuin
(Fig. 1f).
Neuronal over-expression of Sirt1 does not influence
vaso-obliteration and pathologic neovascularization in
OIR
Having confirmed Sirt1 over-expression in Nes-Sirt1
OE retinas,
we then evaluated whether over-expression of Sirt1 in retinal
neurons influences vascular degeneration in a mouse model of
oxygen-induced retinopathy (Fig. 2a). Mouse pups were exposed
to 75% oxygen from postnatal day 7 to 12 to induce retinopathy,
with maximal neovascular response detected at P17
(Fig. 2a)[13,28,29]. Previously, we found that Sirt1 is significantly
upregulated in oxygen-induced retinopathy and conditional
depletion of Sirt1 in retinal neurons significantly dampens vascular
regrowth and precipitates pathologic neovascularization in
Figure 2. Sirt1 over-expression in retinal neurons does not protect against vascular degeneration in oxygen-induced retinopathy
(OIR). a) Schematic illustration of OIR and representative images of retinal flat-mount with OIR and normoxic control retina at P17. To induce
retinopathy, mice were exposed to 75% oxygen from P7 to P12. Retinas were dissected at P17 and stained with Isolectin B4 (red) to visualize vessels.
Lower panels show enlarged areas of normal vessels in control retina and abnormal pathologic neovascularization in OIR retina. Scale bars: top
panels: 1000 mm. Bottom panels: 150 mm. b) Increased Sirt1 levels in Nes-Sirt1
OE retinas compared to control retinas, both in normal room air and with
induced OIR. c) Representative images of retinal vasculature from Nes-Sirt1
OE and littermate controls with induced OIR at P17. Areas of vaso-
obliteration(VO) or pathologic neovascularization (NV) were highlighted in white. d) Quantification of retinal vaso-obliteration in OIR as percent of
total retinal areas in Nes-Sirt1
OE retinas and littermate controls. e) Quantification of pathologic neovascularization in OIR as percent of total retinal
areas in Nes-Sirt1
OE retinas and littermate controls. n=15–20/group. ***p,0.001; n.s.: not significant.
doi:10.1371/journal.pone.0085031.g002
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important for protecting against retinopathy development. In this
study we asked whether over-expression of Sirt1 may be protective
in retinopathy. We first confirmed that in OIR, Sirt1 expression in
flox control is increased compared to normoxic controls, and Nes-
Sirt1
OE retinas in OIR showed additional significantly upregulated
levels of Sirt1 compared to littermate flox control retinas in OIR
(Fig. 2b). Neuronal Sirt1 over-expression, however, does not
significantly influence the levels of vaso-obliteration in OIR
compared to littermate flox controls (control: 23.0261.05% vs.
Nes-Sirt1
OE: 22.6061.09%, n=15–20/group, p=0.79, Fig. 2c,d).
There is also no significant difference in pathologic neovascular-
ization (control: 7.8960.70% vs. Nes-Sirt1
OE: 8.6260.48%,
n=15–20/group, p=0.38, Fig. 2c,e), suggesting that increasing
Sirt1 levels in retinal neurons is not advantageous in protecting
against oxygen-induced retinopathy.
Neuronal over-expression of Sirt1 does not impact retinal
neuron degeneration in retinopathy
In addition to the vascular analysis, we assessed the impact of
neuronal Sirt1 over-expression on retinal neuronal degeneration in
OIR by measuring retinal thickness in paraffin embedded retinal
cross sections. Normally there is significant retinal neuronal
degeneration in OIR retinas after oxygen exposure, compared to
age matched control mice raised in room air. At P17, total retinal
thickness in OIR retinas is reduced approximately 30% compared
to normoxia controls (normoxia: 219.1566.34 mm vs. OIR:
133.8163.46 mm, n=6/group, p,0.0001, Fig. 3a, b). Most
retinal thinning in OIR retinas occurs at the inner nuclear layer
(INL), inner plexiform layer (IPL), and to a lesser extent in
photoreceptor layer (Fig. 3a, b). On the other hand, Nes-Sirt1
OE
retinas in OIR do not show a significant difference in total retinal
thickness at P17 compared to littermate flox controls in OIR in
both central and peripheral areas of retina (Fig. 3c, d). These
data indicate that Sirt1 over-expression in retinal neurons does not
show detectable protection against neuronal degeneration in
retinopathy as assessed by morphology.
Conditional over-expression of Sirt1 in vascular
endothelial cells does not protect against oxygen-
induced retinopathy
Previous studies showed that Sirt1 is important for sprouting
angiogenesis, and endothelial specific knockout of Sirt1 impairs
developmental angiogenesis[24,25]. In addition to generating
Nestin-driven Sirt1 over-expressor mice, we also generated
endothelial specific Sirt1 over-expression mice (Tie2-Sirt1
OE)b y
Figure 3. Neuronal overexpression of Sirt1 does not protect against neuronal degeneration in OIR. a) Representative images of retinal
cross sections from OIR retinas and age-matched normoxic control retinas at P17. Paraffin embedded retinal cross sections were stained with H&E to
visualize cellular structures. b) Total retinal thickness was quantified from OIR retinas and compared to normoxic control retinas. n=6/group. c)
Representative images of retina cross sections from Nes-Sirt1
OE mouse and littermate flox control mice at P17 after OIR. Nes-Sirt1
OE and littermate
control mice were exposed to 75% oxygen from P7 to P12 to induce retinopathy. Retinas were dissected at P17 and paraffin embedded sections were
stained with H&E to visualize cellular structure. d) Quantification of total retinal thickness from OIR exposed Nes-Sirt1
OE mice and littermate flox
control mice. n=6/group. ***p,0.001; n.s.: not significant. Scale bars: 100 mm.
doi:10.1371/journal.pone.0085031.g003
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expression in the retina was previously localized specifically in the
vasculature using Tie2-Cre reporter mice[34]. However, with
induced OIR, conditional over-expression of Sirt1 in Tie2-Sirt1
OE
mice does not impact levels of vaso-obliteration compared to
littermate flox controls (control: 18.1761.88% vs. Tie2-Sirt1
OE:
20.4961.46%, n=8–20; p=0.36; Fig. 4a, b). Pathologic
neovascularization is also not affected in Tie2-Sirt1
OE retinas in
OIR (control: 7.0260.62% vs. Tie2-Sirt1
OE: 7.4260.55%, n=8–
20; p=0.67; Fig. 4a, c). Together these results indicate that over-
expression of Sirt1 in Tie2-expression vascular endothelial cells
does not significantly impact vascular loss and pathologic
neovascularization in OIR.
Resveratrol treatment does not protect against oxygen-
induced retinopathy
To complement the genetic approaches of over-expressing Sirt1
in transgenic mice, we assessed the effect of a Sirt1 activator,
resveratrol, in OIR. Resveratrol is a natural phenol from plant
extracts, and binds Sirt1 through allosteric binding[27]. Resver-
atrol was shown to improve the health and survival of high fat fed
mice[35]. C57Bl/6 mice pups in OIR were treated with oral
gavage of resveratrol (400 mg/kg body weight, daily) from P5 to
P17. Compared to littermate mice fed with vehicle control, mice
fed with resveratrol showed a modest yet significant increase of
vaso-obliteration (control: 24.6061.39% vs. resveratrol:
28.9361.24%, n=15–18/group, p=0.015, Fig. 5a,b). The level
of pathologic neovascularization is not significantly different,
although there is a trend toward suppressing neovascularization
with resveratrol (control: 6.1060.68% vs. resveratrol:
5.4360.41%, n=15–18/group, p=0.19, Fig. 5a,c). These
results suggest that resveratrol does not protect against vascular
pathologies in OIR at the administrated dose. The significantly
increased VO may reflect a Sirt1 independent effect of resveratrol
in directly suppressing vascular growth.
Treatment with Sirt1 activator SRT1720 does not
suppress pathologic neovascularization in oxygen-
induced retinopathy
We next assessed the effect of SRT1720, a highly potent Sirt1
specific activator, in retinopathy. SRT1720 was shown previously
to specifically activate Sirt1 to improve metabolic disorders in
obese mice [26,36]. In this study, C57Bl/6 mouse pups in OIR
were treated with SRT1720 by oral gavage (100 mg/kg body
weight, daily) from P5 to P17 (Fig. 6a). Compared to littermate
mice fed with vehicle control, mice fed with SRT1720 showed a
modest but significant increase of vaso-obliteration (control:
17.8360.99% vs. Sirt1 OE: 21.0160.86%, n=19–20/group,
p=0.02, Fig. 6a,b), suggesting a detrimental effect of increased
vessel loss. No significant difference in pathologic neovasculariza-
tion was observed (control: 9.6260.45% vs. SRT1720:
9.3160.51%, n=19–20/group, p=0.46, Fig. 6a,b). These
results suggest that Sirt1 activator SRT1720 at the administrated
dose does not protect against vascular pathologies in OIR.
Figure 4. Sirt1 over-expression in retinal vascular endothelial cells does not protect against vascular degeneration in OIR. Tie2-
Sirt1
OE and littermate control mice were exposed to 75% oxygen from P7 to P12 to induce retinopathy. Retinas were dissected at P17 and stained
with Isolectin B4 to visualize vessels (red). a) Representative images of retina flat-mounts from Tie2-Sirt1
OE mice and littermate controls at P17 after
OIR. Areas of vaso-obliteration(VO) or pathologic neovascularization (NV) were highlighted in white. Scale bar: 1000 mm. b) Quantification of retinal
vaso-obliteration in OIR as percent of total retinal areas in Tie2-Sirt1
OE and littermate controls. c) Quantification of pathologic NV in OIR as percent of
total retinal areas in Tie2-Sirt1
OE and littermate controls. n=8–20/group; n.s.: not significant.
doi:10.1371/journal.pone.0085031.g004
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In contrast to our previously published data that show marked
effects in retinopathy associated with the lack of Sirt1[12], our
results here reveal that a genetically increased dosage of Sirt1 in
either neurons or vessels within the mouse retina does not alter
vaso-obliteration, pathologic neovascularization, or neuronal
degeneration in oxygen-induced retinopathy. Furthermore, treat-
ment with Sirt1 activators resveratrol or SRT1720, did not show
protective effects against the development of retinopathy. Studies
in different mouse models of human diseases have shown that
while constitutive high levels of sirtuin overexpression (8 to 16 fold)
may cause null or negative effects, inducing moderate amounts of
sirtuins in tissues (lower than 7.5-fold) may confer protective
effects. For instance, we have found previously that a ,16-fold
increase in Sirt1 in hippocampal mouse neurons does not have any
effect in synaptic plasticity, learning or memory[20], whereas in
the heart it was reported that an increase of Sirt1 above 8-fold may
cause a negative effect in cardiac function[37]. In contrast, a
moderate overexpression (,4-fold) in cortical neurons confers a
youthful gene transcription profile in old murine brains[38], and
three to four-fold Sirt1 increase in the intestines of colon cancer
prone mice[39], or in bone marrow lymphocyte progenitors of
p53+/– lymphoma prone mice[38], protect both models from
cancer. In addition, mice producing about twice as much brain
Sirt1 protein as control mice show less anxiety and depression-like
phenotypes[32], with decreased production of b-amyloid and
plaques in a mouse model of Alzheimer’s disease[21], and are
protected against a-synuclein aggregation in a genetic mouse
model of Parkinson’s disease[23]. Although the overexpression
system used herein allowed the transgenic Sirt1 mice to reach the
desired moderate increase of Sirt1 (,4-fold) in neuronal retina, a
level similar to those that produced a protective effect in other
mouse tissues, it was not optimal to alter the course of retinopathy.
Strikingly, most of neuroprotective effects seen in vivo by Sirt1
overexpression have resulted from a mere 2-fold upregulation.
Thus, potentially very low levels of NAD+ in the nervous system
resulting from an overexpression of above 4-fold may offset Sirt1
effects in OIR. In addition, in OIR, the endogenous retinal Sirt1
level is highly upregulated[12], therefore increasing the protein
level of Sirt1 with over-expression of ,4-fold, may not result in
additional gain in enzymatic catalytic activity of lysine deacety-
laion to exert a protective effect. Moreover, endogenous upregula-
tion of Sirt1was observed mostly in retinal ganglion cells[12], the
neuronal cell type most closely associated with superficial layer of
retinal vessels impacted in retinopathy, while as over-expression of
Nestin-driven Sirt1was found in pan-retinal neurons, most
significantly observed in inner nuclear layer composed mainly of
bipolar cells. This difference of expression in cell specificity may
also account for the lack of protective effects in Nes-Sirt1 mice,
and suggest that cell specific expression of Sirt1 may play a role in
determining directional regulation of blood vessel growth in
retinopathy.
It is noteworthy that lysine acetylation of proteins is a transiently
regulated mechanism in response to rapid and recurrent changes
in tissue metabolic conditions. We have formerly reported that
Sirt1 is highly induced in OIR, and proposed that Sirt1 promoted
vascular regrowth in part by controlling the expression of
angiogenic factors through mediating deacetylation and stability
of hypoxia-induced factor (HIF) 1a and 2a[12]. Thus, a
Figure 5. Resveratrol treatment does not suppress vascular pathologies in OIR. C57Bl/6 mouse pups were exposed to 75% oxygen from P7
to P12 to induce retinopathy. Littermate mouse pups were treated with resveratrol or vehicle control through daily oral gavage from P5 to P17.
Retinas were dissected at P17 and stained with Isolectin B4 to visualize vessels. a) Representative images of retina flat-mounts from resveratrol treated
mice and littermate vehicle controls at P17 after OIR. Areas of retinal vaso-obliteration(VO) in OIR and pathologic neovascularization(NV) were
highlighted in white. Scale bar: 1000 mm. b) Quantification of vaso-obliteration as percent of total retinal areas in resveratrol treated mice compared
to littermate controls. c) Quantification of pathologic NV in OIR as percent of total retinal areas in resveratrol treated mice compared to littermate
controls. n=15–18/group; *p,0.05; n.s.: not significant.
doi:10.1371/journal.pone.0085031.g005
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regulated transient induction in response to environmental need,
might alter acetylation levels of key factors involved in angiogen-
esis and other cellular processes, thereby hampering any Sirt1-
dependent acute transient regulation in OIR. At present,
thousands of proteins have been identified to be regulated by
acetylation and among those hundreds are relevant for normal
physiology, aging and pathology of the brain, and are targets of
Sirt1[19]. However, limited information is known about protein
acetylation in retinopathy and eye diseases. Recently, acetylation
of retinal histones was found to increase inflammation in diabetic
retinopathy[40], and overexpression of histone deacetylase 4
(HDAC4) was found to promote neuronal survival and protect
against retinal degeneration[41]. Further studies will allow us to
gain deeper insights in the role of protein acetylation and its
regulation by sirtuins and other deacetylases in retinal diseases.
In contrast to limited in vivo studies of Sirt1 mutant mice in
retinal diseases, small molecule Sirt1 activators have been
evaluated in the eye in several studies. Since their discovery, Sirt1
activators have been investigated in various animal models and
diseases including cancer, cardiovascular diseases and neurode-
generation, involving various drug forms and dosages[42]. While
many have shown significant effects, others have none. One of the
most challenging aspects of evaluating resveratrol’s efficacy is the
wide variety of available formulations, dosages, as well as routes
and times of administration, all of which greatly influence the
experimental results[43]. Among the few studies performed in the
retina, it was found that resveratrol suppressed light-induced
retinal degeneration by decreasing outer nuclear layer apoptosis
and thinning, thereby preserving visual function as detected by
electroretinography[44]. In human retinal pigment epithelium,
resveratrol reduces oxidative stress and hyperproliferation[45]. In
addition, a study in a rat model of oxygen-induced retinopathy
showed that resveratrol modulates nitric oxide synthase, however
the phenotypic effect on in vivo retinopathy was not thoroughly
characterized[46]. In this previous study, 30 mg/kg resveratrol,
normally administered orally, was injected intravitreally. The
results differed compared to our experiments, where mice treated
with oral gavage of 400 mg/kg resveratrol did not show significant
protection in OIR. Interestingly, our study of resveratrol treatment
through oral gavage showed a modest detrimental effect of
increased vaso-obliteration, which may reflect a direct anti-
angiogenic effect of resveratrol. This was also shown in our
previous study in which oral resveratrol treatment in Vldlr
2/2
mice suppressed pathologic subretinal neovascularization[47], as
well as in a separate study where resveratrol suppressed laser-
induced choroidal neovascularization in a Sirt1 independent
manner[48], suggesting that the specific role of resveratrol is likely
disease and pathology dependent. In addition, a recent chemical
screening study indicates that resveratrol is an inhibitor of
SOCS3(suppressor of cytokine signalling 3) expression[49],
depletion of which in vascular endothelial cells negatively impacts
retinopathy[34]. This negative regulation of resveratrol on SOCS3
may also contribute in part to the lack of its protective effect in
OIR.
Compared to resveratrol, SRT1720, a potent Sirt1 activator,
has not been as thoroughly tested. Nonetheless, existing data on
SRT1720 show that it produces diverse effects in multiple diseases,
Figure 6. Sirt1 activator SRT1720 does not suppress vascular pathologies in OIR. C57Bl/6 mouse pups were exposed to 75% oxygen from
P7 to P12 to induce retinopathy. Littermate mouse pups were treated with SRT1720 or vehicle controls through daily oral gavage from P5 to P17.
Retinas were dissected at P17 and stained with Isolectin B4 to visualize vessels. a) Representative images of retina flat-mounts from SRT1720 treated
mice and littermate vehicle controls at P17 after OIR. Areas of vaso-obliteration(VO) or pathologic neovascularization(NV) were highlighted in white.
Scale bar: 1000 mm. b) Quantification of retinal vaso-obliteration in OIR as percent of total retinal areas in SRT1720 treated mice compared to
littermate controls. c) Quantification of pathologic NV in OIR as percent of total retinal areas in SRT1720 treated mice compared to littermate controls.
n=18–20/group; *p,0.05; n.s.: not significant.
doi:10.1371/journal.pone.0085031.g006
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implicated as a potential therapeutic for type 2 diabetes[26,36].
SRT1720 has also been shown to suppress inflammation in a
mouse model of asthma[50], and promote tumor cell migration
and metastasis of breast cancer in mice[51]. However, the effects
of SRT1720 in the nervous system and in the retina, have been
scarcely addressed. Although our data did not show SRT1720 or
resveratrol providing protection in retinopathy, a study in a mouse
model of multiple sclerosis revealed that oral administration of this
drug prevents axonal loss of retinal ganglion cells and optic nerve
in optic neuritis, as did resveratrol[52].
While our data demonstrate that Sirt1 over-expression in the
retinas increase the expression of Sirt1 target genes, whether
induction of Sirt1 with a genetic approach or pharmacologic
treatment indeed leads to increased Sirt1 enzymatic activity and
hence physiologic function, remains undetermined due to techni-
cal challenges. Measuring Sirt1 enzymatic activity in tissue
extraction, particularly in small samples such as the retina, is
difficult. Fluorescent Sirt1 enzymatic assay has potential artifacts
and thereby considered not reliable by most researchers[53].
Measuring Sirt1 reaction products O-acetyl adenosine diphos-
phate ribose by mass spectrometry, or nicotinamide with nicotin-
amidase PNC1 and ortho-phthalaldehyde (OPT)[27] are not only
technically difficult, but so far both assays have only been carried
out with immunopurified protein mixed with externally provided
substrates. Yet, in living tissue, the physiological regulation of Sirt1
relies on allosteric regulation of Sirt1, NAD
+ bioavailability, and/
or nicotinamide levels in specific cellular compartments, all of
which are lost in homogenized cellular extraction. In addition,
whole tissues like retinas, potentially express all seven isoforms of
Sirtuins, which may potentially interfere with the Sirt1 enzymatic
assay. Future development of more reliable, accurate Sirt1 activity
assay for tissue extracts will help overcome these technical
limitations and greatly benefit research in Sirt1’s biologic activity.
In conclusion, while lack of Sirt1 promotes retinopathy in
mouse OIR as we previously reported[12], the current study with
Sirt1 genetic overexpression or oral treatment with gavaged Sirt1
activating compounds such as resveratrol or SRT1720 does not
support their additive protective effect in retinopathy. Further
studies evaluating different levels of Sirt1 overexpression, induc-
tion of this sirtuin in specific cell types, diverse activators’
concentrations and routes of administration, as well as assessing
the resultant Sirt1 enzymatic activity may allow us to examine
more in depth whether increasing levels of Sirt1 may serve as a
potential therapeutic approach to treat or prevent retinopathy.
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